» Articles » PMID: 22087794

Gastric Neuroendocrine Carcinoma After Long-term Use of Proton Pump Inhibitor

Overview
Publisher Informa Healthcare
Specialty Gastroenterology
Date 2011 Nov 18
PMID 22087794
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

We present a case of a gastric neuroendocrine carcinoma in a patient with a history of long-term proton pump inhibitor (PPI) use. A 49-year-old man using PPI for the last 15 years due to gastroesophageal reflux disease developed progressive dysphagia, dyspepsia and weight loss. Upper gastrointestinal endoscopy, endoscopic ultrasonography and abdominal CT diagnosed a malignant tumor localized to a hiatal hernia. Fasting serum chromogranin A and gastrin concentrations were elevated (32 nmol/l and 159 pmol/l, respectively). Helicobacter pylori PCR analysis of antral biopsies was negative. Biopsies from endoscopically normal oxyntic mucosa showed enterochromaffin-like (ECL) cell hyperplasia. Tumor biopsies revealed a poorly differentiated neuroendocrine carcinoma. Sevier-Munger staining, immunohistochemistry and electron microscopy indicated ECL cell as origin of the tumor cells. Concerns have previously been raised about the safety of long-term PPI use due to a possible increased risk of cancer. This case illustrates a patient with a poorly differentiated neuroendocrine carcinoma with ECL cell characteristics probably induced by hypergastrinemia secondary to long-term PPI use.

Citing Articles

A pharmacovigilance study of the association between proton pump inhibitors and tumor adverse events based on the FDA adverse event reporting system database.

Zhang Y, Duan D, Tian Q, Wang C, Wei S Front Pharmacol. 2025; 15:1524903.

PMID: 39749203 PMC: 11694325. DOI: 10.3389/fphar.2024.1524903.


A Study on the Glucose Breath Test Positivity Rate and Occurrence of Small Intestine Bacterial Overgrowth-Related Symptoms Caused by Long-Term Use of Proton Pump Inhibitor (PPI) Versus Potassium-Competitive Acid Blocker (P-CAB) in Elderly Patients:....

Lim N, Lim S, Chung W Adv Pharmacol Pharm Sci. 2024; 2024:6069151.

PMID: 39502577 PMC: 11537742. DOI: 10.1155/2024/6069151.


Epidemiological, Clinical and Biological Hemogram Features in a Cohort of Neuroendocrine Tumor Patients.

Cimpeanu R, Salmen T, Boldeanu L, Mustata M, Fortofoiu D, Cazacu S Curr Health Sci J. 2024; 50(2):256-266.

PMID: 39371064 PMC: 11447499. DOI: 10.12865/CHSJ.50.02.11.


Proton Pump Inhibitors and Cancer Risk: A Comprehensive Review of Epidemiological and Mechanistic Evidence.

Sawaid I, Samson A J Clin Med. 2024; 13(7).

PMID: 38610738 PMC: 11012754. DOI: 10.3390/jcm13071970.


Multiple Gastric Neuroendocrine Tumors Associated with Long-term Use of a Proton Pump Inhibitor and a Potassium-competitive Acid Blocker.

Nagao S, Yabuuchi Y, Tanaka K, Morihisa Y, Kobayashi T, Akiyama S Intern Med. 2023; 63(14):2001-2010.

PMID: 38008447 PMC: 11309866. DOI: 10.2169/internalmedicine.2857-23.